• Antibody treatment for ‘bubble boy’ disease

    In a clinical trial, participants were given an antibody to CD117, a cell surface marker, in an effort to wipe out their defective blood stem cells without high-risk chemotherapy or radiation.

  • Progress toward precision health

    A perspective piece from Stanford scientists provides an overview of the value of precision health, its progress, challenges and how it can improve health at the individual and population level.

  • Magazine explores new frontiers

    The winter issue of Stanford Medicine magazine highlights science that pushes boundaries to save lives and considers ethical questions that are a fundamental part of research.

  • How our brains prepare for action

    Mentally running through a routine improves performance, but how that works isn’t clear. Now, a new tool — brain-machine interface — suggests the answer lies in how our brains prepare for action.

  • Ioannidis on antidepressant efficacy

    In a highly comprehensive meta-analysis of more than 500 clinical trials, researchers from around the world have drawn conclusions about the efficacy of 21 different antidepressants.

  • Neuroscience awards named for Barres

    The five-year awards from the Chan Zuckerberg Initiative will help fuel research into the biology of neurodegenerative diseases. The awards honor a Stanford neuroscientist who died in December.

  • Iron triggers lung transplant infection

    Iron enables a common mold to take root in lung transplant recipients, according to Stanford researchers who led a study that offers a new perspective for understanding and treating these pulmonary infections.

  • Schneider on disease and data sculptures

    Many infectious diseases, including malaria, are marked by cyclical ups and downs. David Schneider takes a creative approach to making sense of those ups and downs.

  • Drug Discovery Conference set for April 23-24

    The two-day conference at Stanford will bring together experts from academia, industry and government to discuss drug policy, research and business opportunities.

  • Gerald Reaven, who coined ‘Syndrome X,’ dies

    Gerald Reaven’s decades of research at Stanford helped show that insulin resistance could lead to Type 2 diabetes and multiple other diseases.

2024 ISSUE 1

Psychiatry’s new frontiers